Overview
The Vitae Pharmaceuticals business model is to address the critical issues confronting the industry’s small molecule drug research efforts: Innovation, Speed and Capital Efficiency.
We address high unmet medical need conditions using a novel structure-based drug discovery engine run by world-class discovery and early development scientists targeting known, promising, hard-to-drug targets. Vitae Pharmaceuticals’ three lead programs demonstrate our ability to achieve innovation, speed and capital efficiency in drug discovery.
Vitae Pharmaceuticals Performance Record:
Meeting Goals of Innovation, Speed and Capital Efficiency
| Time to achieve | |||||
|---|---|---|---|---|---|
| Novel, patentable structures | Animal PD proof-of-principle |
Value realization via deal | Upfront committed cash | Year | |
| Renin | 7 mos. | 14 mos. | wholly owned by Vitae | n/a | n/a |
| 11ß-HSD-1 | 2 mos. | 16 mos. | 21 mos. | $37 MM | 2007 |
| BACE | 6 mos. | 14 mos. | 18 mos. | $42 MM | 2009 |
Innovation / Speed
On average, Vitae Pharmaceuticals' discovery engine has produced novel leads with animal proof-of-concept data within 14-16 months. This includes assay development, generation of crystal structures, SBDD using proprietary platform, etc.
Capital Efficiency
The annual incremental cost of a Vitae Pharmaceuticals discovery program is ~$5 million; and time from program start-to-deal has consistently been under 2 years.